Cognition Therapeutics, Inc. is a clinical-stage neuroscience company developing oral medications designed to treat neurodegenerative disorders
The sheer number of patients and caregivers affected by the combined burden of Alzheimer’s disease and dementia with Lewy bodies (DLB) is the driving force behind Cognition’s mission to develop safe, effective, easy-to-administer treatment options that slow the progression of these life-altering diseases.
Cognition is advancing the development of an oral medication – zervimesine (also CT1812) – to treat these diseases.
Zervimesine is a small molecule, oral therapeutic product candidate being investigated for the treatment of Alzheimer’s disease and DLB. We believe zervimesine shows promise in protecting neurons in the brain by binding to the sigma-2 receptor complex and restoring cellular damage response processes such as autophagy, cholesterol synthesis, and protein trafficking. As a potential daily oral medication, zervimesine represents a treatment paradigm shift from invasive and burdensome to convenient and comfortable.
Learn more about our ongoing and planned clinical studies here.
